As of this writing, Eli Lilly & Co. (LLY) is up 16.34% on the day, making it one of the biggest gainers in the market today. The surge comes after a positive update from Bloomberg regarding its experimental weight-loss pill, orforglipron.
The trial results showed that patients lost an average of 7.9% of their body weight over a 40-week period, outperforming Novo Nordisk’s Ozempic shot by a significant margin. This news has sent shockwaves through the market, with investors and analysts alike taking notice of Lilly’s potential to become the leading player in the obesity drug market.
But what does this mean for you as an investor? Let’s break it down:
The Numbers:
- LLY is up 16.34% today, making it one of the biggest gainers in the market.
- The company’s stock price has increased by $120.08 to reach a new high of $854.98.
- Lilly’s weight-loss pill trial results show that patients lost an average of 7.9% of their body weight over a 40-week period, outperforming Novo Nordisk’s Ozempic shot.
The Context:
Lilly has been working on developing its own weight-loss pill for some time now, and these latest trial results are a significant step forward in that process. The company is confident that if orforglipron is approved, it will be able to launch worldwide without supply constraints – a major advantage over Novo Nordisk’s Ozempic shot.
The Risks:
While the news is certainly positive for Lilly investors, there are still risks associated with investing in any stock. The company faces competition from other players in the market, including Pfizer and AstraZeneca, which have also been working on developing their own weight-loss pills.
Additionally, regulatory approval of orforglipron will be a crucial step forward for the company, and there is always a risk that it may not receive the necessary approvals to launch its product.
What’s Next:
Lilly has stated that it expects to submit orforglipron for weight management by the end of this year, with an application for type 2 diabetes anticipated in 2026. The company will need to continue working on perfecting its pill and navigating regulatory hurdles before it can bring it to market.
Get Ahead of the Game:
Want to stay up-to-date on the latest stock news and trends? Sign up for our free daily SMS list by tapping here. and get ahead of the game.
